Skip to main content
SpringerLink
Log in

Dual-Acting Angiotensin Receptor–Neprilysin Inhibition

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Lowering blood pressure by pharmacologic intervention reduces the incidence of cardiovascular events. Nevertheless, despite the widespread availability of effective antihypertensive medications, the vast majority of hypertensive patients worldwide continue to have inadequate blood pressure control. The development of new antihypertensive drugs could contribute to improving the hypertension control rate, and the blockade of new pathophysiologic pathways involved in blood pressure regulation would offer additional benefits. The dual inhibition of the angiotensin II receptor and neprilysin could provide clinical benefits in a range of cardiovascular diseases, including hypertension and heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Neaton JD, Wentworth D: Serum cholesterol blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992, 152:56–64.

    Article  CAS  PubMed  Google Scholar 

  2. Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  3. Weiner DE, Tighiouart H, Amin MG, et al.: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004, 15:1307–1315.

    Article  PubMed  Google Scholar 

  4. Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217–223.

    PubMed  Google Scholar 

  5. Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105–1187.

    Article  CAS  PubMed  Google Scholar 

  6. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  CAS  PubMed  Google Scholar 

  7. Turnbull F, Blood Pressure Lowering Treatment Trialists Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527–1535.

    Article  CAS  PubMed  Google Scholar 

  8. •• Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. This metaanalysis shows that all the classes of blood pressure lowering drugs have a similar effect in reducing cardiovascular events for a given reduction in blood pressure.

    Article  CAS  PubMed  Google Scholar 

  9. Wolf-Maier K, Cooper RS, Kramer H, et al.: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10–17.

    Article  CAS  PubMed  Google Scholar 

  10. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339:321–328.

    Article  CAS  PubMed  Google Scholar 

  11. Pandey KN: Biology of natriuretic peptides and their receptors. Peptides 2005, 26:901–932.

    Article  CAS  PubMed  Google Scholar 

  12. Gardner DG, Chen S, Glenn DJ, Grigsby CL: Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007, 49:419–426.

    Article  CAS  PubMed  Google Scholar 

  13. Bevan EG, Connell JM, Doyle J, et al.: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992, 10:607–613.

    Article  CAS  PubMed  Google Scholar 

  14. Richards AM, Wittert GA, Crozier IG, et al.: Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993, 11:407–416.

    Article  CAS  PubMed  Google Scholar 

  15. Ando S, Rahman MA, Butler GC, et al.: Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995, 26:1160–1166.

    CAS  PubMed  Google Scholar 

  16. Ferro CJ, Spratt JC, Haynes et al.: Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998, 97:2323–2330.

    CAS  PubMed  Google Scholar 

  17. Campbell DJ: Vasopeptidase inhibition: a double-edged sword? Hypertension 2003, 41:383–389.

    Article  CAS  PubMed  Google Scholar 

  18. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17(Suppl 1):S37–S43.

    CAS  Google Scholar 

  19. Robl JA, Sun CQ, Stevenson J, et al.: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997, 40:1570–1577.

    Article  CAS  PubMed  Google Scholar 

  20. Trippodo NC, Robl JA, Asaad MM, et al.: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998, 11(3 Pt 1):363–372.

    Article  CAS  PubMed  Google Scholar 

  21. Liao WC, Vesterqvist O, Delaney C, et al.: Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharmacol 2003, 56:395–406.

    Article  CAS  PubMed  Google Scholar 

  22. Nawarskas JJ, Anderson JR: Omapatrilat: a unique new agent for the treatment of cardiovascular disease. Heart Dis 2000, 2:266–274.

    CAS  PubMed  Google Scholar 

  23. Mitchell GF, Izzo JL Jr, Lacourcière Y, et al.: Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the Conduit Hemodynamics of Omapatrilat International Research Study. Circulation 2002, 105:2955–2961.

    Article  CAS  PubMed  Google Scholar 

  24. Kostis JB, Packer M, Black HR, et al.: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103–111.

    Article  CAS  PubMed  Google Scholar 

  25. • Fryer RM, Segreti J, Banfor PN, et al.: Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008, 153:947–955. This paper describes the mechanisms involved in bradykinin-mediated angioedema.

    Article  CAS  PubMed  Google Scholar 

  26. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A: Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004, 164:910–913.

    Article  PubMed  Google Scholar 

  27. •• Gu J, Noe A, Chandra P, et al.: Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010, 50:401–414. This manuscript describes for the first time the molecular structure of LCZ696.

    Article  CAS  PubMed  Google Scholar 

  28. •• Ruilope LM, Dukat A, Böhm M, et al.: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375:1255–1266. This paper reports the results of a trial using LCZ696 for concomitant inhibition of neprilysin and the angiotensin II type 1 receptor in treating cardiovascular disorders.

    Article  CAS  PubMed  Google Scholar 

  29. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Hypertension Unit. Hospital 12 de Octubre, Av. Córdoba s/n, 28041, Madrid, Spain

    Julian Segura & Luis M. Ruilope

Authors
  1. Julian Segura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis M. Ruilope
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julian Segura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Segura, J., Ruilope, L.M. Dual-Acting Angiotensin Receptor–Neprilysin Inhibition. Curr Hypertens Rep 13, 74–78 (2011). https://doi.org/10.1007/s11906-010-0166-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-010-0166-7

Keywords

Search

Navigation